TQB2450

TQB2450 is a monoclonal antibody developed by Chia Tai Tianqing Pharmaceutical. Its targets are PD-L1 and PD-1 (the sponsor names PD-L1). The sponsor states: TQB2450 is a humanised monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 binding to PD-1 and B7.1 receptors on T cells, restoring T-cell activity and enhancing immune response. ClinicalTrials.gov describes the intervention as: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potenti. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT04523272 (A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer), in renal cell carcinoma and non-small-cell lung cancer. The largest, NCT04523272, plans to enrol 528 participants (actual) with primary completion was scheduled for 2025-06 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.